Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations

Clinical Chemistry

Volumn 44, Issue 9, 1998, Pages 1931-1936

  Duell, P Barton ^a   Wheaton, David L ^a   Shultz, Amy ^a   Nguyen, Hien ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN; MELATONIN;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CANCER; HORMONE ACTION; HUMAN; HUMAN CELL; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MACROPHAGE;

EID: 0031753715     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.9.1931     Document Type: Article

References (50)

1. Lerner AB, Case JD, Heinzelman RV. Structure of melatonin. J Am Chem Soc 1959;81:6084-5.
2. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991;79:C153-8.
3. Lewy AJ, Sack RL, Blood ML, Bauer VK, Cutler NL, Thomas KH. Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. Ciba Found Symp 1995;183:303-7.
4. Dijk DJ, Boulos Z, Eastman CI, Lewy AJ, Campbell SS, Terman M. Light treatment for sleep disorders: consensus report. II. Basic properties of circadian physiology and sleep regulation. J Biol Rhythms 1995;10:113-25.
5. Reiter RJ, Tan D-X, Poeggeler BR, Menendez-Pelaez A, Chen L-D, Saarela S. Melatonin as a free radical scavenger: implications for aging and age related diseases. Ann N Y Acad Sci 1994;719:1-12.
6. Tan D-X, Chen L-D, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993;1:57-60.
7. Pieri C, Maurizio M, Moroni F, Recchioni R, Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 1994;55:271-6.
8. Poeggeler B, Reiter RJ, Hardeland R, Tan D-X, Barlow-Walden LR. Melatonin and structurally-related, endogenous indoles act as potent electron donors and radical scavengers in vitro. Redox Report 1996;2:179-84.
9. 2-induced lipid peroxidation in rat brain homogenates is greatly reduced by melatonin. Neurosci Lett 1995;195:203-5.
10. Poeggeler B, Reiter RJ, Tan D-X, Chen L-D, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 1993;14:151-68.
11. Pierpaoli W, Yi CX, Dall'Ara A. Aging-postponing effects of circadian melatonin: experimental evidence, significance and possible mechanisms. Int J Neurosci 1990;51:339-40.
12. Armstrong SM, Redman JR. Melatonin: a chronobiotic with antiaging properties? Med Hypotheses 1991;34:300-9.
13. Grad BR, Rozencwaig R. The role of melatonin and serotonin in aging: update. Psychoneuroendocrinology 1993;18:283-95.
14. Bonn D. Melatonin's multifarious marvels: miracle or myth? Lancet 1996;347:184.
15. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95.
16. Steinberg D, Lewis A. Conner Memorial Lecture-oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062-71.
17. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Investig 1991;88:1785-92.
18. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975-8.
19. Jialal I, Devaraj S. Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Clin Chem 1996;42:498-506.
20. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.
21. Reaven PD, Witztum JL. Oxidized low density lipoproteins in atherogenesis: role of dietary modification. Annu Rev Nutr 1996; 16:51-71.
22. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995;346:36-8.
23. Kwiterovich PO Jr. The effect of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis. J Am Diet Assoc 1997;97(Suppl 7):S31-41.
24. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis 1995;38:129-54.
25. Duell PB. The role of dietary antioxidants in prevention of atherosclerosis. Endocrinologist 1995;5:347-56.
26. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease. Ann Intern Med 1995;123:860-72.
27. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
28. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.
29. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. NIH 75-628. Washington, DC: US Department of Health, Education, and Welfare, 1974:1.
30. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL resulting in inhibition of high affinity binding to cultured human fibroblasts. Diabetes 1990;39:1257-63.
31. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of high density lipoprotein impairs HDL receptor-mediated cholesterol efflux. Diabetes 1991;40:377-84.
32. Chait A, Mazzone T. A secretory product of human monocyte-derived macrophages stimulates low density lipoprotein receptor activity in arterial smooth muscle cells and skin fibroblasts. Arteriosclerosis 1982;2:134-41.
33. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
34. Esterbauer H, Dieber-Rotheneder M, Waeg G, Rabl H. Effect of antioxidants on oxidative modification of LDL. Ann Med 1991;23: 573-81.
35. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
36. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Investig 1986;77:757-61.
37. Hartree EF. Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 1972;48:422-7.
38. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968;9:693-700.
39. Cagnacci A, Elliott JA, Yen SS. Amplification of pulsatile LH secretion by exogenous melatonin in women. J Clin Endocrinol Metab 1991;73:210-2.
40. Waldhauser F, Lieberman HR, Lynch HJ, Waldhauser M, Herkner K, Frisch H, et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, and testosterone or cortisol. Neuroendocrinology 1987;46:125-30.
41. Jialal I, Grundy SM. Effect of dietary supplementation with α-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 1992;33:899-906.
42. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995;345:1408.
43. Nagtegaal E, Smits M, Swart W, van der Meer G, Kerkhof G. Melatonin secretion and coronary heart disease. Lancet 1995; 346:1299.
44. Pieri C, Marra M, Gáspár R, Damjanovich S. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Biochem Biophys Res Commun 1996;222:256-60.
45. Kelly MR, Loo G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J Pineal Res 1997;22:203-9.
46. Abuja PM, Liebmann P, Hayn M, Schauenstein K, Esterbauer H. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett 1997;413:289-93.
47. Seegar H, Mueck AO, Lippert TH. Effect of melatonin and metabolites on copper-mediated oxidation of low density lipoprotein. Br J Clin Pharmacol 1997;44:283-4.
48. Marshall KA, Reiter RJ, Poeggeler B, Aruoma OI, Halliwell B. Evaluation of the antioxidant activity of melatonin in vitro. Free Radical Biol Med 1996;21:307-15.
49. Aviram M, Fuhrman B, Maor I, Brook GJ. Serotonin increases macrophage uptake of oxidized low density lipoprotein. Eur J Clin Chem Clin Biochem 1992;30:55-61.
50. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation. A dose response study. Arterioscler Thromb 1995;15:190-8.